The aim of this study was to determine the side effects of standard antituberculosis therapy with isoniazid, rifampicin, pyrazinamide and streptomycine in patients treated for tuberculosis. One hundred eighty nine patients with proven tuberculosis, who initially received standard antituberculosis therapy, were retrospectively studied. Begaud and coll's method of side effects drugs imputability elaborated in 1999 was used in our study. Side effects related to therapy were present in 31.7% of the studied population. Gastrointestinal side effect was the most common (13.2%), isoniazid, rifampicin and pyrazinamide were often incriminated. The significant risk factors of hepatotoxicity were female gender (OR : 10.59) and concomitant hepatotoxic drugs (OR 6). Chocleovestibular toxicity was associated significantly with female gender (OR : 8.03) and diabetes mellitus (OR : 6.13). Patients aged above 50, proved to be at risk for pyrazinomide intolerance and females for streptomycine. The study did not reveal any susceptibility to isoniazid and rifadine intolerance.